Jeffrey Weitz
#76,870
Most Influential Person Now
Researcher
Jeffrey Weitz's AcademicInfluence.com Rankings
Jeffrey Weitzcomputer-science Degrees
Computer Science
#2897
World Rank
#3034
Historical Rank
Machine Learning
#229
World Rank
#232
Historical Rank
Artificial Intelligence
#388
World Rank
#395
Historical Rank
Database
#484
World Rank
#507
Historical Rank
Download Badge
Computer Science
Jeffrey Weitz's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Jeffrey Weitz Influential?
(Suggest an Edit or Addition)According to Wikipedia, Jeffrey Ian Weitz is a Canadian bioscientist, currently the Canada Research Chair in Thrombosis and Endowed Chair in Cardiovascular Medicine at McMaster University.
Jeffrey Weitz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Edoxaban versus warfarin in patients with atrial fibrillation. (2013) (3988)
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (2014) (3577)
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020) (1949)
- Oral apixaban for the treatment of acute venous thromboembolism. (2013) (1942)
- Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer (2000) (1517)
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. (1990) (1216)
- A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. (1996) (1191)
- Apixaban for extended treatment of venous thromboembolism. (2013) (1134)
- A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. (1999) (1125)
- Idarucizumab for Dabigatran Reversal. (2015) (1093)
- Low-molecular-weight heparins. (1997) (1088)
- Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events (2002) (1027)
- Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism (1998) (995)
- Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. (1996) (872)
- Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (830)
- Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. (2003) (741)
- Accuracy of clinical assessment of deep-vein thrombosis (1995) (738)
- Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (725)
- Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism (2017) (713)
- Idarucizumab for Dabigatran Reversal — Full Cohort Analysis (2017) (612)
- Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source (2018) (579)
- Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. (2005) (555)
- Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development (2009) (542)
- Thrombosis: A Major Contributor to Global Disease Burden (2014) (542)
- Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. (2011) (528)
- Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (2017) (521)
- Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (2014) (471)
- Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. (1988) (462)
- Thrombosis: A Major Contributor to Global Disease Burden (2014) (450)
- Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis (2000) (411)
- Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (410)
- Factor XI antisense oligonucleotide for prevention of venous thrombosis. (2014) (398)
- Vitamin K antagonists in heart disease: Current status and perspectives (Section III) (2013) (385)
- The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. (2014) (384)
- Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis (1995) (383)
- A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. (1994) (370)
- Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. (1999) (360)
- Update on Antithrombotic Therapy: New Anticoagulants (2010) (339)
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation (2010) (333)
- The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways (2002) (333)
- Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and Platelet-Independent Mechanisms (2014) (332)
- Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. (2000) (328)
- Medical device‐induced thrombosis: what causes it and how can we prevent it? (2015) (327)
- New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (301)
- A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. (1990) (298)
- Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. (1990) (286)
- Prosthetic Heart Valve Thrombosis. (2016) (278)
- A Test in Context: D-Dimer. (2017) (270)
- When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH (2016) (267)
- New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. (2012) (265)
- Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) (2013) (251)
- CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. (1991) (249)
- Sensitivity and Specificity of a Rapid Whole-Blood Assay for D-Dimer in the Diagnosis of Pulmonary Embolism (1998) (247)
- Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data (2002) (246)
- Characterization of the stress-inducing effects of homocysteine. (1998) (237)
- A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. (1995) (235)
- Strain history dependence of the nonlinear stress response of fibrin and collagen networks (2013) (233)
- Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. (2021) (225)
- New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (220)
- Thrombosis: a major contributor to global disease burden. (2014) (216)
- Thrombosis: a major contributor to the global disease burden (2014) (215)
- Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. (1998) (214)
- Management of Suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and d-dimer Testing (2001) (213)
- Prognostic utility and characterization of cell-free DNA in patients with severe sepsis (2012) (208)
- Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (201)
- New Anticoagulants for Treatment of Venous Thromboembolism (2008) (201)
- Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers (2014) (195)
- Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research (2020) (194)
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (2018) (190)
- More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT (1996) (179)
- Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial (2015) (179)
- A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. (1997) (173)
- Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin (1994) (173)
- General mechanisms of coagulation and targets of anticoagulants (Section I) (2013) (172)
- Assays for Measuring Rivaroxaban: Their Suitability and Limitations (2010) (170)
- Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel (2014) (161)
- Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies (2013) (159)
- Patients with severe sepsis vary markedly in their ability to generate activated protein C. (2004) (159)
- Characterization of a Mouse Model for Thrombomodulin Deficiency (2001) (157)
- Plasma fibronectin supports hemostasis and regulates thrombosis. (2014) (152)
- Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor (2004) (150)
- Idarucizumab: The Antidote for Reversal of Dabigatran (2015) (149)
- Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement (2010) (149)
- New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (148)
- Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. (1996) (144)
- Anticoagulants in heart disease: current status and perspectives. (2007) (143)
- Coagulation assays. (2005) (143)
- A Diagnostic Strategy Involving a Quantitative Latex d-Dimer Assay Reliably Excludes Deep Venous Thrombosis (2003) (142)
- Clinical Utility of a Rapid Whole-Blood d-Dimer Assay in Patients with Cancer Who Present with Suspected Acute Deep Venous Thrombosis (1999) (141)
- Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study (2018) (139)
- Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran (2015) (139)
- Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. (2016) (138)
- Overview of the new oral anticoagulants: opportunities and challenges. (2015) (137)
- Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis (2019) (136)
- A simple clinical model for the diagnosis of deep‐vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process (1998) (135)
- New anticoagulant drugs. (2001) (133)
- The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. (1997) (132)
- Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. (2015) (131)
- Direct Thrombin Inhibitors in Acute Coronary Syndromes: Present and Future (2002) (129)
- Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. (2014) (128)
- Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface* (2002) (127)
- An Evaluation of d-Dimer in the Diagnosis of Pulmonary Embolism (2006) (127)
- G-Protein–Coupled Receptors as Signaling Targets for Antiplatelet Therapy (2009) (125)
- Elastase-mediated fibrinogenolysis by chemoattractant-stimulated neutrophils occurs in the presence of physiologic concentrations of antiproteinases (1987) (125)
- Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19 (2021) (124)
- Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. (2008) (123)
- Venous thrombosis (2015) (122)
- Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. (1998) (121)
- Evolving use of new oral anticoagulants for treatment of venous thromboembolism. (2014) (120)
- The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro (1998) (120)
- Therapeutic strategies for thrombosis: new targets and approaches (2020) (119)
- Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial (2005) (118)
- Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants (2013) (113)
- Periprocedural management and approach to bleeding in patients taking dabigatran. (2012) (112)
- Increased neutrophil elastase activity in cigarette smokers. (1987) (112)
- Reversal agents for non-vitamin K antagonist oral anticoagulants (2018) (111)
- Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis (2015) (111)
- The mechanism of action of thrombin inhibitors. (2000) (111)
- New oral anticoagulants in development (2009) (110)
- Inferior Vena Cava Ligation Rapidly Induces Tissue Factor Expression and Venous Thrombosis in Rats (2009) (108)
- Comparison of Low-Intensity Warfarin Therapy With Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism (2004) (107)
- Evidence for Allosteric Linkage between Exosites 1 and 2 of Thrombin* (1997) (107)
- Antithrombotic therapy in patients undergoing percutaneous coronary intervention. (2001) (107)
- Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins (1993) (106)
- Emerging anticoagulants for the treatment of venous thromboembolism (2006) (106)
- Safety of Withholding Heparin in Pregnant Women With a History of Venous Thromboembolism (2001) (105)
- Global public awareness of venous thromboembolism (2015) (104)
- Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review (2017) (104)
- Fibrin Clot Lysis by Thrombolytic Agents Is Impaired in Newborns due to a Low Plasminogen Concentration (1992) (103)
- Molecular Basis for the Susceptibility of Fibrin-bound Thrombin to Inactivation by Heparin Cofactor II in the Presence of Dermatan Sulfate but Not Heparin* (2001) (101)
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. (2020) (100)
- Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. (1998) (97)
- Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. (2000) (97)
- The status of new anticoagulants (2006) (96)
- Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers (2004) (96)
- Novel oral anticoagulants in gastroenterology practice. (2013) (96)
- Contribution of Host-Derived Tissue Factor to Tumor Neovascularization (2008) (96)
- Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. (2016) (95)
- Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study (2021) (93)
- Oral Direct Factor Xa Inhibitors (2012) (91)
- The blood compatibility challenge part 1: Blood-contacting medical devices: The scope of the problem. (2019) (91)
- Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. (2011) (91)
- Exosites 1 and 2 Are Essential for Protection of Fibrin-bound Thrombin from Heparin-catalyzed Inhibition by Antithrombin and Heparin Cofactor II* (1999) (90)
- Factor Xa or thrombin: Is thrombin a better target? (2007) (90)
- Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. (2017) (89)
- Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial (2016) (88)
- Edoxaban for treatment of venous thromboembolism in patients with cancer (2015) (85)
- Delayed but not Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine Model of Sepsis (2015) (85)
- Limitations of Impedance Plethysmography in the Diagnosis of Clinically Suspected Deep-Vein Thrombosis (1993) (85)
- Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. (1996) (85)
- Comparison of the Accuracy of Impedance Plethysmography and Compression Ultrasonography in Outpatients with Clinically Suspected Deep Vein Thrombosis (1995) (84)
- Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study (2001) (84)
- Investigation of the Anticoagulant Mechanisms of a Covalent Antithrombin-Heparin Complex* (1998) (83)
- Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina (2001) (83)
- COVID-19 coagulopathy, thrombosis, and bleeding (2020) (83)
- Zinc: An important cofactor in haemostasis and thrombosis (2013) (82)
- Development of an assay for in vivo human neutrophil elastase activity. Increased elastase activity in patients with alpha 1-proteinase inhibitor deficiency. (1986) (81)
- Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation (2015) (80)
- Antithrombotic therapy in patients undergoing coronary angioplasty. (1995) (80)
- Factor Xa and thrombin as targets for new oral anticoagulants. (2011) (78)
- Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin* (2000) (76)
- Evidence That Both Exosites on Thrombin Participate in Its High Affinity Interaction with Fibrin* (2003) (75)
- A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. (1999) (75)
- Antibody‐Based Ticagrelor Reversal Agent in Healthy Volunteers (2019) (75)
- Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis. (1991) (74)
- Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. (2000) (74)
- Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. (2020) (74)
- Homocysteine-dependent Alterations in Mitochondrial Gene Expression, Function and Structure (1998) (74)
- Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. (2002) (74)
- Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. (1997) (73)
- New developments in anticoagulants: Past, present and future (2017) (73)
- Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. (2001) (72)
- Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? (2013) (72)
- Real‐world variability in dabigatran levels in patients with atrial fibrillation (2015) (72)
- Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. (2012) (71)
- Novel oral anticoagulants and reversal agents: Considerations for clinical development. (2015) (71)
- New antithrombotic agents (1999) (70)
- Antithrombotic therapy during percutaneous coronary intervention: The seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy (2005) (70)
- Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. (1988) (68)
- Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants (2015) (68)
- In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. (2002) (68)
- Abelacimab for Prevention of Venous Thromboembolism. (2021) (67)
- Thromboprophylaxis in surgical patients. (2003) (67)
- Factors XI and XII as Targets for New Anticoagulants (2017) (67)
- An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces (2017) (66)
- The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE (2016) (66)
- The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model (1992) (66)
- Update on heparin: what do we need to know? (2010) (65)
- Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. (1992) (65)
- Beyond heparin and warfarin: the new generation of anticoagulants (2007) (64)
- Direct thrombin inhibitors. (2002) (64)
- Risk of recurrent venous thromboembolism according to baseline risk factor profiles. (2018) (63)
- Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. (2017) (63)
- Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care (2018) (62)
- Long Range Communication between Exosites 1 and 2 Modulates Thrombin Function* (2009) (62)
- Elevated tissue factor procoagulant activity in CD133‐positive cancer cells (2007) (61)
- Incorporation of Vitronectin into Fibrin Clots (2002) (61)
- Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th New Antithrombotic Drugs : Antithrombotic (2012) (60)
- Emerging anticoagulant strategies. (2017) (60)
- Lubricant-Infused Surfaces with Built-In Functional Biomolecules Exhibit Simultaneous Repellency and Tunable Cell Adhesion. (2018) (60)
- Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry (2018) (58)
- Milvexian for the Prevention of Venous Thromboembolism. (2021) (58)
- Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease: Focus on the COMPASS Trial (2019) (58)
- Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease (2020) (58)
- Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis (2020) (58)
- Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents (2014) (57)
- Selective d-Dimer Testing for Diagnosis of a First Suspected Episode of Deep Venous Thrombosis (2013) (57)
- Comparison of Heparin- and Dermatan Sulfate-mediated Catalysis of Thrombin Inactivation by Heparin Cofactor II* (1999) (56)
- Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. (2016) (55)
- Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. (2004) (55)
- Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. (1993) (55)
- Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease (2016) (55)
- Bivalent Binding to γA/γ′-Fibrin Engages Both Exosites of Thrombin and Protects It from Inhibition by the Antithrombin-Heparin Complex* (2008) (54)
- Translational Success Stories: Development of Direct Thrombin Inhibitors (2012) (54)
- Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. (2011) (53)
- The Role of Protected Extracellular Compartments in Interactions between Leukocytes, and Platelets, and Fibrin/Fibrinogen Matrices a (1992) (53)
- Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism (2015) (53)
- Mechanism of Catalysis of Inhibition of Factor IXa by Antithrombin in the Presence of Heparin or Pentasaccharide* (2003) (52)
- Heparan sulfate: antithrombotic or not? (2003) (52)
- Identification of the Mechanism Responsible for the Increased Fibrin Specificity of TNK-Tissue Plasminogen Activator Relative to Tissue Plasminogen Activator* (2000) (52)
- A novel approach to thrombin inhibition. (2003) (52)
- Factor XI and factor XII as targets for new anticoagulants. (2016) (52)
- Characterization of the Interactions of Plasminogen and Tissue and Vampire Bat Plasminogen Activators with Fibrinogen, Fibrin, and the Complex of d-Dimer Noncovalently Linked to Fragment E* (1998) (52)
- Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE) (2016) (50)
- The Asp272–Glu282 Region of Platelet Glycoprotein Ibα Interacts with the Heparin-binding Site of α-Thrombin and Protects the Enzyme from the Heparin-catalyzed Inhibition by Antithrombin III* (2000) (50)
- A replacement for warfarin: the search continues. (2007) (50)
- Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. (2001) (50)
- Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. (2018) (49)
- Urgent Need to Measure Effects of Direct Oral Anticoagulants. (2016) (49)
- Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state [see comments] (1993) (48)
- Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. (2019) (48)
- New oral anticoagulants: which one should my patient use? (2012) (48)
- Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Study (2001) (47)
- New anticoagulants: beyond heparin, low‐molecular‐weight heparin and warfarin (2005) (47)
- Role of the tissue factor pathway in the biology of tumor initiating cells. (2010) (47)
- Thrombophilia and new anticoagulant drugs. (2004) (47)
- Hospitalized COVID-19 Patients and Venous Thromboembolism: A Perfect Storm. (2020) (46)
- Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. (2018) (46)
- Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. (2013) (45)
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis (2014) (44)
- Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen. (2002) (43)
- Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome (2014) (42)
- Meeting the Unmet Needs in Anticoagulant Therapy (2010) (41)
- The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. (1997) (41)
- Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. (2015) (41)
- Effect of fibrinogen degradation products and lung ground substance on surfactant function. (1990) (41)
- Advances in Antithrombotic Therapy: Novel Agents (1995) (41)
- Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. (1993) (40)
- New antithrombotic agents. (1998) (40)
- New oral anticoagulants: A view from the laboratory (2012) (39)
- Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation (2008) (39)
- Novel Antithrombotic Strategies for Treatment of Venous Thromboembolism. (2020) (39)
- Antithrombotic Agents: New Directions in Antithrombotic Therapy (2019) (38)
- Activation of blood coagulation by plaque rupture: mechanisms and prevention. (1995) (38)
- Parenteral Anticoagulants (2008) (38)
- Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients (2020) (38)
- Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction. (2000) (38)
- Mechanism of Action of Plasminogen Activators (1999) (37)
- A High Affinity Interaction of Plasminogen with Fibrin Is Not Essential for Efficient Activation by Tissue-type Plasminogen Activator* (2011) (37)
- Idarucizumab for dabigatran overdose (2016) (37)
- Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry (2019) (37)
- Effects of Intermittent Pneumatic Calf Compression On Postoperative Thrombin and Plasmin Activity (1986) (37)
- Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID‐19: A single‐center prospective longitudinal study (2021) (37)
- Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet‐mediated events during thrombus formation (2012) (36)
- Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. (2008) (36)
- Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway (2015) (36)
- Vasoflux, a new anticoagulant with a novel mechanism of action. (1999) (36)
- Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development. (1999) (36)
- Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants. (2020) (36)
- Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis In Myocardial Infarction) (2018) (36)
- New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes (2012) (35)
- Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke (2018) (35)
- Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia. (1984) (35)
- Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects (1992) (34)
- New Anticoagulants for Treatment of Venous Thromboembolism (2004) (34)
- Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. (2003) (34)
- Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. (2012) (34)
- A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery (2010) (34)
- Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study (2019) (34)
- Dabigatran etexilate for prevention of venous thromboembolism (2008) (34)
- Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers (2018) (34)
- Life-Threatening Thrombosis in Mice With Targeted Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin (2003) (34)
- Conductive Electrochemically Active Lubricant‐Infused Nanostructured Surfaces Attenuate Coagulation and Enable Friction‐Less Droplet Manipulation (2018) (33)
- Identification of Dp71 Isoforms in the Platelet Membrane Cytoskeleton (2002) (33)
- NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. (2016) (33)
- Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha 1-proteinase inhibitor. (1992) (33)
- HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions (2009) (33)
- Localization of the Thrombin-binding Domain on Prothrombin Fragment 2* (1998) (33)
- The contact activation system as a potential therapeutic target in patients with COVID‐19 (2020) (32)
- Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome. (1992) (32)
- Antithrombin-Heparin Covalent Complex: A Possible Alternative to Heparin for Arterial Thrombosis Prevention (2002) (32)
- New anticoagulant therapy. (2005) (32)
- Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa (2016) (32)
- Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week. (2021) (32)
- Batroxobin Binds Fibrin with Higher Affinity and Promotes Clot Expansion to a Greater Extent than Thrombin* (2013) (32)
- Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism (2016) (32)
- Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure (2015) (31)
- Histidine-rich Glycoprotein Binds Fibrin(ogen) with High Affinity and Competes with Thrombin for Binding to the γ′-Chain* (2011) (31)
- Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease (2014) (30)
- New anticoagulants. (2005) (30)
- Utility of ultrasound imaging of the lower extremities in the diagnostic approach in patients with suspected pulmonary embolism (2001) (30)
- Anticoagulation therapy: Dabigatran and risk of myocardial infarction (2012) (30)
- Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial (2018) (30)
- Faculty Opinions recommendation of Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial. (2020) (30)
- APIXABAN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: DATA FROM THE AMPLIFY TRIAL (2014) (30)
- Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE (2020) (30)
- Free Protein S Deficiency May Be Found in Patients with Antiphospholipid Antibodies who Do not Have Systemic Lupus Erythematosus (1996) (30)
- Immunologic Identification of the Cleavage Products from the Aα- and Bβ-Chains in the Early Stages of Plasmin Digestion of Fibrinogen (1986) (30)
- Advances in Antithrombotic Therapy (2019) (30)
- Ximelagatran: the first oral direct thrombin inhibitor (2004) (29)
- New anticoagulants: Moving beyond the direct oral anticoagulants (2020) (29)
- Conformational Changes in Thrombin When Complexed by Serpins* (2001) (29)
- Decreased Thrombin Activity of Fibrin Clots Prepared in Cord Plasma Compared with Adult Plasma (1996) (29)
- HD1, a Thrombin-directed Aptamer, Binds Exosite 1 on Prothrombin with High Affinity and Inhibits Its Activation by Prothrombinase* (2006) (29)
- Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. (2016) (29)
- Role of phenotypic and genetic testing in managing clopidogrel therapy. (2014) (28)
- New anticoagulants. (2005) (28)
- Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs (2009) (28)
- Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. (2000) (28)
- Mechanisms Responsible for Catalysis of the Inhibition of Factor Xa or Thrombin by Antithrombin Using a Covalent Antithrombin-Heparin Complex* (2003) (27)
- Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. (2016) (27)
- Emerging Anticoagulant Drugs (2003) (27)
- Do Coagulation Screening Tests Detect Increased Generation of Thrombin and Plasmin in Sick Newborn Infants? (1993) (27)
- Synthesis and radioiodination of a stannyl oligodeoxyribonucleotide. (1997) (27)
- Lysis of surface-localized fibrin clots by adsorbed plasminogen in the presence of tissue plasminogen activator. (1996) (27)
- Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants (2017) (27)
- Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin. (1990) (27)
- HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. (2015) (27)
- Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation (2008) (27)
- Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients (2019) (27)
- Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease: Lessons From the COMPASS Trial (2019) (26)
- Faculty Opinions recommendation of Intrinsic pathway of coagulation and thrombosis. (2020) (26)
- Contact Activation Inhibitor, AB023, in Heparin-Free Hemodialysis: Results of a Randomized Phase 2 Clinical Trial. (2021) (26)
- Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial (2015) (26)
- The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations (2018) (26)
- Factor XI as a Target for New Anticoagulants (2021) (26)
- Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase* (2001) (26)
- 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants (2018) (26)
- Clinical implications of incidental venous thromboembolism in cancer patients (2019) (26)
- The Asp(272)-Glu(282) region of platelet glycoprotein Ibalpha interacts with the heparin-binding site of alpha-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III. (2000) (25)
- Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome (2014) (25)
- Rapid quantitative D‐dimer to exclude pulmonary embolism: a prospective cohort management study (2016) (25)
- Surface modification with polyethylene glycol-corn trypsin inhibitor conjugate to inhibit the contact factor pathway on blood-contacting surfaces. (2011) (25)
- Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients (2013) (25)
- Thrombin-activable Fibrinolysis Inhibitor Attenuates (DD)E-mediated Stimulation of Plasminogen Activation by Reducing the Affinity of (DD)E for Tissue Plasminogen Activator (2000) (25)
- Development of a radioimmunoassay for the fibrinogen-derived peptide B beta 1-42. (1986) (24)
- Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization. (2019) (24)
- Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study (2019) (24)
- Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. (2000) (24)
- Direct thrombin inhibitors in cardiac disease (2007) (24)
- Binding of Anti-GRP78 Autoantibodies to Cell Surface GRP78 Increases Tissue Factor Procoagulant Activity via the Release of Calcium from Endoplasmic Reticulum Stores* (2010) (23)
- Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry (2019) (23)
- Modes and consequences of thrombin's interaction with fibrin. (2004) (23)
- Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. (1995) (23)
- A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury (2006) (23)
- Effects on Thrombin Generation of Single Injections of Hirulog™ in Patients with Calf Vein Thrombosis (1994) (22)
- Lubricant-Infused PET Grafts with Built-In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells. (2019) (22)
- New anticoagulant strategies. Current status and future potential. (1994) (22)
- Heparin and angiogenesis: size matters! (2003) (22)
- Zn2+ Mediates High Affinity Binding of Heparin to the αC Domain of Fibrinogen* (2013) (22)
- Pharmacology and clinical potential of direct thrombin inhibitors. (2005) (22)
- Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models (2014) (22)
- Hypercoagulable states. (2010) (21)
- The Effect of Antithrombin III-Independent Thrombin Inhibitors and Heparin on Fibrin Accretion onto Fibrin-Coated Polyethylene (1993) (21)
- Interactions of plasminogen and fibrinogen with model silica glass surfaces: adsorption from plasma and enzymatic activity studies. (1994) (21)
- Expanding use of new oral anticoagulants (2014) (21)
- The real decoy: an antidote for factor Xa-directed anticoagulants. (2013) (21)
- Heparin Synergistically Enhances Interleukin-11 Signaling through Up-regulation of the MAPK Pathway* (2006) (21)
- Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer (2020) (21)
- Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. (2014) (21)
- Periprocedural Management of New Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation (2014) (20)
- Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. (2018) (20)
- Unanswered questions in venous thromboembolism. (2009) (19)
- North American Thrombosis Forum, AF Action Initiative Consensus Document. (2016) (19)
- Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells (2016) (19)
- Low-dose warfarin in rehabilitating stroke survivors. (2002) (19)
- Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery (2019) (18)
- Platelet polyphosphate: the long and the short of it. (2017) (18)
- Acute coronary syndromes: a focus on thrombin. (2002) (18)
- Potential of new anticoagulants in patients with cancer. (2010) (18)
- Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin. (2006) (18)
- Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence (2020) (18)
- ‘Real world’ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry (2015) (17)
- Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients (2021) (17)
- Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. (2015) (17)
- Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease (2012) (17)
- A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. (1990) (17)
- Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation (2015) (17)
- Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations (2017) (17)
- Appropriate Apixaban Dosing: Prescribers Take Note. (2016) (16)
- Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment (2019) (16)
- Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial (2018) (16)
- Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. (1997) (16)
- Like Fibrin, (DD)E, the Major Degradation Product of Crosslinked Fibrin, Protects Plasmin from Inhibition by α2-antiplasmin (2001) (16)
- Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. (2019) (16)
- Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy (2015) (16)
- Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism (1996) (16)
- Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials (2020) (16)
- Thrombosis and anticoagulation. (1999) (16)
- Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. (2016) (16)
- Targeted Gene Sequencing Identifies Variants in the Protein C and Endothelial Protein C Receptor Genes in Patients With Unprovoked Venous Thromboembolism (2013) (15)
- D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. (2016) (15)
- Anticoagulation therapy in 2015: where we are and where we are going (2015) (15)
- Modification of Polyurethane with Polyethylene Glycol–Corn Trypsin Inhibitor for Inhibition of Factor Xlla in Blood Contact (2012) (15)
- Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. (2020) (15)
- PERIOPERATIVE ADVERSE OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION TAKING EDOXABAN OR WARFARIN: ANALYSIS OF THE ENGAGE AF-TIMI 48 TRIAL (2015) (15)
- Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD (2021) (15)
- Reversal of Direct Oral Anticoagulants: Current Status and Future Directions (2017) (14)
- Once versus twice daily aspirin after coronary bypass surgery: a randomized trial (2017) (14)
- Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis (1991) (14)
- Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. (1999) (14)
- Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi (2019) (14)
- Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease (2020) (14)
- The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release (1991) (13)
- Hypercoagulable states. (2011) (13)
- New anticoagulants (2005) (13)
- Biological rationale for the therapeutic role of specific antithrombins. (1996) (13)
- Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin (2016) (13)
- Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits (2014) (13)
- New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty (2011) (13)
- Evolution of Thrombosis (1987) (13)
- Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. (2017) (13)
- Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation (2018) (13)
- Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. (2012) (13)
- Anticoagulation for Mechanical Heart Valves: Will Oral Factor Xa Inhibitors Be Effective? (2017) (13)
- Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial (2019) (12)
- Activated platelets form protected zones of adhesion on fibrinogen and fibronectin-coated surfaces (1993) (12)
- New Anticoagulants (2003) (12)
- Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study (2017) (12)
- Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation. (1995) (12)
- Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials (2019) (12)
- Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism (2021) (12)
- Venous Thromboembolism : Mechanisms , Treatment , and Public Awareness (2008) (12)
- Dual surface modification with PEG and corn trypsin inhibitor: effect of PEG:CTI ratio on protein resistance and anticoagulant properties. (2012) (12)
- Dabigatran Reversal with Idarucizumab. (2017) (12)
- Mortality Risk Profiles for Sepsis: A Novel Longitudinal and Multivariable Approach (2019) (12)
- Polysiloxane Nanofilaments Infused with Silicone Oil Prevent Bacterial Adhesion and Suppress Thrombosis on Intranasal Splints. (2021) (12)
- Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. (2010) (12)
- By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin. (2012) (12)
- Abstract 569: Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and -Independent Mechanisms (2014) (12)
- Antithrombins: their potential as antithrombotic agents. (1992) (12)
- Hematologic Problems in the Surgical Patient (2017) (12)
- Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation. (2004) (11)
- Reduced Plasminogen Binding and Delayed Activation Render γ′-Fibrin More Resistant to Lysis than γA-Fibrin* (2014) (11)
- Timing the First Postoperative Dose of Anticoagulants: Lessons Learned From Clinical Trials. (2015) (11)
- Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model (2018) (11)
- Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function (2016) (11)
- The mTORC pathway in the antiphospholipid syndrome. (2014) (11)
- A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin (2016) (11)
- ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES (2012) (11)
- Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary interventions. (2000) (11)
- Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation (2015) (11)
- Warfarin after bioprosthetic aortic valve implantation. (2012) (11)
- Exosite 2-Directed Ligands Attenuate Protein C Activation by the Thrombin-Thrombomodulin Complex. (2017) (11)
- Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials (2021) (11)
- Selective factor Xa inhibition for thromboprophylaxis (2008) (11)
- Interactions of thermally denatured fibrinogen on polyethylene with plasma proteins and platelets. (1992) (11)
- Faculty Opinions recommendation of American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. (2020) (11)
- Importance of family history as a risk factor for venous thromboembolism. (2011) (10)
- Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery (2021) (10)
- Dabigatran monitoring made simple? (2013) (10)
- Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE (2021) (10)
- A Specific Antidote for Reversal of Anticoagulation by Direct and Indirect Inhibitors of Coagulation Factor Xa (2013) (10)
- 6 Mechanism of action of the thrombolytic agents (1990) (10)
- Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. (2018) (10)
- Inhibition of osteolytic bone metastasis by unfractionated heparin (2008) (10)
- Rivaroxaban and dabigatran for suppression of mechanical heart valve-induced thrombin generation. (2019) (9)
- Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta‐analysis (2020) (9)
- Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). (2001) (9)
- Glycosaminoglycans bind factor Xa in a Ca2+-dependent fashion and modulate its catalytic activity. (2003) (9)
- Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies (2018) (9)
- New antithrombotics. (1995) (9)
- Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia (2019) (9)
- Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation (2020) (9)
- Global public awareness about atrial fibrillation (2017) (9)
- Localization of heparin and low-molecular-weight heparin in the rat kidney (2004) (9)
- Advances in Thrombosis and Hemostasis: An Introduction to the Compendium. (2016) (9)
- Guidance, guidelines, and communications (2014) (8)
- Wells PS, Hirsh J, Anderson DR, et al: Accuracy of clinical assessment of deep-vein thrombosis (1995) (8)
- Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE (2021) (8)
- Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis (2021) (8)
- Otamixaban in acute coronary syndromes (2009) (8)
- A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. (2016) (8)
- Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. (2021) (8)
- Long range communication between exosites 1 and 2 modulates thrombin function. (2015) (8)
- Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty. (2009) (8)
- Initial treatment of venous thromboembolism (2006) (8)
- Antithrombotic therapy in patients undergoing coronary angioplasty. (1998) (8)
- MAA868 locks factor XIa in a zymogen-like state. (2019) (8)
- INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONS (2015) (8)
- Addressing the burden of hospital‐related venous thromboembolism: the role of extended anticoagulant prophylaxis (2018) (8)
- Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis (2009) (8)
- Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required? (2020) (8)
- Use of novel antithrombotic agents for COVID‐19: Systematic summary of ongoing randomized controlled trials (2021) (8)
- Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism (2012) (7)
- Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study (2019) (7)
- Emerging themes in the treatment of venous thromboembolism (2006) (7)
- Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study (2017) (7)
- Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial (2021) (7)
- Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. (2021) (7)
- Abstract 17392: Gastrointestinal Bleeding With Edoxaban versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (2015) (7)
- Genetics of coagulation: what the cardiologist needs to know. (2013) (7)
- Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. (2022) (7)
- Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials (2016) (7)
- Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves (2018) (7)
- Dabigatran Reversal with Idarucizumab. (2017) (7)
- Polyphosphate-induced Thrombosis in Mice is Factor XII-Dependent and is Attenuated by Histidine-rich Glycoprotein. (2021) (6)
- Emerging therapies for stroke prevention in atrial fibrillation (2005) (6)
- Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study (2015) (6)
- Ciraparantag for enoxaparin reversal: Adding to the evidence. (2016) (6)
- Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. (2019) (6)
- In the presence of phospholipids, glycosaminoglycans potentiate factor Xa-mediated protein C activation by modulating factor Xa activity. (2007) (6)
- Development and Application of Assays for Elastase‐Specific Fibrinogen Fragments a (1991) (6)
- Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin. (2002) (6)
- AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa. (2019) (6)
- IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONS (2016) (6)
- A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study (2017) (6)
- Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran. (2018) (6)
- The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate (1993) (6)
- Identification and characterization of a factor Va-binding site on human prothrombin fragment 2 (2019) (6)
- The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. (2021) (6)
- Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality (2021) (6)
- Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial (2015) (6)
- New and Emerging Anticoagulant Therapies for Venous Thromboembolism (2010) (6)
- Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE (2021) (6)
- Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus (2018) (6)
- Faculty Opinions recommendation of Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. (2019) (6)
- Chapter 122 – Overview of Hemostasis and Thrombosis (2018) (5)
- Use of a synthetic homologue of human fibrinopeptide A for production of a monoclonal antibody specific for the free peptide. (1989) (5)
- Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. (2019) (5)
- Anticoagulation for ST-segment elevation myocardial infarction. (2009) (5)
- State-of-the-art-mini review: Dual pathway inhibition to reduce arterial and venous thromboembolism. (2022) (5)
- Faculty Opinions recommendation of Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. (2019) (5)
- 45. Functional comparison of (DD)E with fibrin (1998) (5)
- Hemorrhagic complications in association with percutaneous coronary intervention: can the risk be attenuated? (2000) (5)
- Recent advances in understanding, diagnosing and treating venous thrombosis (2020) (5)
- Hospitalized COVID-19 Patients and Venous Thromboembolism (2020) (5)
- Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data (2014) (5)
- Bivalirudin, thrombin and platelets: clinical implications and future directions. (2003) (5)
- Hypercoagulability and coronavirus disease 2019–associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms (2020) (5)
- The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand (2013) (5)
- Abstract 16418: Reinitiation of Antithrombotic Therapy After Emergency Procedures or After an Uncontrolled or Life Threatening Bleeding Event. Initial Experience From the Re-verse Ad Trial (2015) (5)
- New oral anticoagulants for stroke prevention in atrial fibrillation (2011) (5)
- New Anticoagulant Strategies (1993) (5)
- Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome (2019) (5)
- Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial (2018) (5)
- Prevention and treatment of venous thromboembolism during pregnancy (2009) (5)
- Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. (2019) (5)
- Faculty Opinions recommendation of Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. (2014) (4)
- Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials (2022) (4)
- Dysfibrinogenemia in obstructive liver disease. (1987) (4)
- The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. (2018) (4)
- Abstract 213: Effect of Idarucizumab on Intracranial Bleeding in Dabigatran-treated Patients: Initial Results From RE-VERSE AD (2016) (4)
- Rivaroxaban for prevention and treatment of venous thromboembolism. (2019) (4)
- Procoagulants for management of bleeding with the new oral anticoagulants (2013) (4)
- Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. (2020) (4)
- Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). (2015) (4)
- Influence of Body Mass Index on Clinical Outcomes in Venous Thromboembolism: Insights from GARFIELD-VTE. (2021) (4)
- Faculty Opinions recommendation of Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. (4)
- Faculty Opinions recommendation of Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. (4)
- Routine booster doses of hepatitis B vaccine for health care workers are not necessary. (2000) (4)
- Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism (2020) (4)
- Another oral thrombin inhibitor for stroke prevention in atrial fibrillation? (2010) (4)
- Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis (2019) (4)
- ESC position paper Anticoagulants in heart disease : current status and perspectives ‡ (2007) (4)
- The Antidote for Reversal of Dabigatran (2015) (4)
- Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban (2021) (4)
- Activated thrombin‐activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin‐dependent plasmin generation on thrombin‐activated platelets (2020) (4)
- Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin (2021) (3)
- Evidence-Based Clinical Practice Guidelines American College of Chest Physicians and Prevention of Thrombosis, 9th ed: Antiplatelet Drugs : Antithrombotic Therapy (2012) (3)
- ANALYSIS OF THE BLEEDING AND THROMBOEMBOLIC RISK WITH CONCOMITANT USE OF ANTIPLATELET TREATMENT IN THE AMPLIFY TRIAL (2014) (3)
- 73 Disruption of vitronectin-mediated binding of plasminogen activator inhibitor-1 to fibrin stimulates tissue-type plasminogen activator induced fibrinolysis (1997) (3)
- Producing Fluorine- and Lubricant-Free Flexible Pathogen- and Blood-Repellent Surfaces Using Polysiloxane-Based Hierarchical Structures. (2022) (3)
- Chapter 140 – Hypercoagulable States (2018) (3)
- Practice Guidelines (8th Edition) Clinical of Chest Physicians Evidence-Based Parenteral Anticoagulants: American College (2008) (3)
- Extended Treatment of Venous Thromboembolism. (2017) (3)
- More on acutely injured patients receiving dabigatran. (2012) (3)
- Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial (2018) (3)
- Vorapaxar, combination antiplatelet therapy, and stroke. (2014) (3)
- The Changing Landscape in Oral Anticoagulation – The Last Pieces of the Puzzle (2013) (3)
- Orally active direct thrombin inhibitors. (2003) (3)
- Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism (2018) (3)
- Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent (2018) (3)
- New anticoagulants: an update. (2004) (3)
- Assessment and Management of Gastrointestinal Hemorrhage in the Setting of Direct Oral Anticoagulants: The Hematology Perspective (2016) (3)
- New Anticoagulant Drugs (2001) (3)
- An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. (2016) (3)
- Review in translational hematology New anticoagulants (2004) (3)
- Mechanism of action of the thrombolytic agents. (1990) (2)
- Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism (2020) (2)
- Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. (2021) (2)
- Response by Chan and Weitz to Letter Regarding Article, "Antithrombotic Agents: New Directions in Antithrombotic Therapy". (2019) (2)
- 4 Initial Experience With Idarucizumab in Dabigatran-Treated Patients Presenting With Acute Gastrointestinal Hemorrhage: Interim Results from the RE-VERSE AD Study (2015) (2)
- New oral anticoagulants (2003) (2)
- Are Ticks the Answer to Medical Device-Associated Clotting? (2019) (2)
- Oncogenic events regulating tissue factor expression (2009) (2)
- An update on new anticoagulants. (2003) (2)
- Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial (2020) (2)
- Chapter 149 – Antithrombotic Drugs (2018) (2)
- A PoTENtial Antidote: A Prohemostatic Factor Xa Variant for Reversal of Direct Oral Anticoagulants. (2016) (2)
- Ciraparantag as a potential universal anticoagulant reversal agent. (2021) (2)
- Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential (2017) (2)
- Transparent and Highly Flexible Hierarchically Structured Polydimethylsiloxane Surfaces Suppress Bacterial Attachment and Thrombosis Under Static and Dynamic Conditions. (2022) (2)
- COMPARISON OF JNJ9375, A THROMBIN EXOSITE 1-DIRECTED ANTIBODY, WITH APIXABAN FOR THROMBOPROPHYLAXIS AFTER ELECTIVE KNEE REPLACEMENT SURGERY: TEXT-TKR STUDY (2019) (2)
- Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding. (2015) (2)
- Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19]. (2020) (2)
- OC-14 Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study (2021) (2)
- COMPARISON OF THE EFFECT OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS AND WARFARIN ON MECHANICAL HEART VALVE-INDUCED THROMBIN GENERATION (2015) (1)
- Neutrophils and the protein C pathway (2003) (1)
- The effect of plasma proteins and platelet release products on the anti-thrombin activities of standard heparin and dermatan sulfate (1992) (1)
- Factor XI antisense oligonucleotide for venous thrombosis. (2015) (1)
- Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial (2019) (1)
- Management of venous thromboembolism: present and future. (2004) (1)
- Comprar Hematology 7th Ed. Basic Principles and Practice | Ronald Hoffman | 9780323357623 | Elsevier Internacional (2017) (1)
- Randomized trial to examine the effect of ASA dose or ASA dosing frequency on ASA resistance after coronary artery bypass graft surgery (2013) (1)
- Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? (2014) (1)
- Abstract of the 12th International Congress on Thrombosis Plenary lectures of the 12th International Congress on Thrombosis Plenary lectures of the 12tLimitations of impedance plethysmography (IPG) in the diagnosis of clinically suspected deep-vein thrombosis (DVT) (1992) (1)
- Abstract 15113: Idarucizumab in Dabigatran-Treated Patients Requiring Emergency Surgery or Intervention: Updated/Final Results From the RE-VERSE AD Study (2017) (1)
- 792 Do Concurrent Gastroprotective Agents Impact Gastrointestinal Bleeding Rates in Edoxaban Users? Results From the ENGAGE-AF TIMI 48 Trial (2016) (1)
- Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Parenteral Anticoagulants : Antithrombotic (2012) (1)
- Identification of the histidine‐rich glycoprotein domains responsible for contact pathway inhibition (2021) (1)
- Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. Reply. (2019) (1)
- Fibrous hydrogels under biaxial confinement (2022) (1)
- Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors (2022) (1)
- Health Care Resource Utilization in Patients Requiring Urgent Surgical/Interventional Management While Taking Dabigatran: Interim Results From the Re-Verse Ad Study (2016) (1)
- OP0269 BIOMARKERS TO PREDICT RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS (2022) (1)
- Recommendation on the Nomenclature for Anticoagulants: Updated Communication from the ISTH SSC Subcommittee on the Control of Anticoagulation. (2023) (1)
- Heparin-Binding Domain of Antithrombin Life-Threatening Thrombosis in Mice With Targeted Arg 48-to-Cys Mutation of the Print (2003) (1)
- Arterial thrombosis is accelerated in histidine-rich glycoprotein deficient mice (2015) (1)
- AbstractRivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (2017) (1)
- Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness (2022) (1)
- Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older (2021) (1)
- A Vascular Graft On‐a‐Chip Platform for Assessing the Thrombogenicity of Vascular Prosthesis and Coatings with Tuneable Flow and Surface Conditions (2022) (1)
- Should warfarin be restarted after warfarin-associated intracranial hemorrhage? (2012) (1)
- 2350Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452 (2019) (1)
- Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study (2019) (1)
- Elevated Fibrinopeptide A and B Levels during Thrombolytic Therapy: Real or Artefactual? (1996) (1)
- oligonucleotides attenuates catheter thrombosis in rabbits Selective depletion of factor XI or factor XII with antisense (2014) (1)
- Zinc Enhances the Protection of Fibrin-Bound Thrombin from Antithro Inhibition. (2007) (1)
- Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial (2022) (1)
- P3863Trauma victims requiring dabigatran reversal with idarucizumab in RE-VERSE AD (2018) (1)
- Faculty Opinions recommendation of Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. (2020) (1)
- Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done? (2017) (1)
- In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding (2017) (1)
- Heparin compromises streptokinase-induced arterial patency in rabbits. (2005) (1)
- Anticoagulants in Heart Disease Position Paper Syndromes: ESC Working Group on ThrombosisTask Force on New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary (2012) (1)
- Idrabiotaparinux treatment for venous thromboembolism (2012) (1)
- Identification of a unique glomerular factor X activator in murine lupus nephritis. (1999) (1)
- New Anticoagulants Hirudin and Hirulog in the Treatment of Acute Coronary Syndromes (1995) (1)
- Risk Factors for Thrombosis and Bleedings Prevention of Arterial and Venous Thrombosis Treatment of VTE and Adverse Reactions (1999) (1)
- Impact of World Thrombosis Day campaign (2017) (1)
- Therapeutic strategies for thrombosis: new targets and approaches (2020) (1)
- Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. (2018) (1)
- Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis (2021) (1)
- 98 – Pulmonary Embolism (2012) (1)
- HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. (2015) (1)
- Obituary for Dr. Clive Kearon. (2020) (0)
- Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa (2017) (0)
- Update on Antithrombotic Therapy Update on Antithrombotic Therapy New Anticoagulants (2010) (0)
- 262 Initial Experience With Idarucizumab in Dabigatran-Treated Patients Presenting With Acute Traumatic Injuries: Interim Results From the RE-VERSE AD Study (2015) (0)
- PCV110 COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY (2009) (0)
- The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism (2017) (0)
- On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease (2022) (0)
- Faculty Opinions recommendation of The use of artificial neural network analysis can improve the risk-stratification of patients presenting with suspected deep vein thrombosis. (2020) (0)
- Faculty Opinions recommendation of Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. (2020) (0)
- IDENTIFICATION OF A NEUTROPHIL ELASTASE CLEAVAGE SITE ON THE Act -CHAIN OF PRIMATE FIBRINOGEN (1987) (0)
- Challenges facing early career women in thrombosis and hemostasis—meeting the needs of the next generation (2022) (0)
- 504 Subtle Differences in Commercial Heparins Can Have Serious Consequences for Cardiopulmonary Bypass Patients: a randomized controlled trial (2012) (0)
- Advances in Thrombosis and Hemostasis (2016) (0)
- Pathogenesis of Venous Thromboembolism (2016) (0)
- Faculty Opinions recommendation of Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. (0)
- Highly Stable Hierarchically Structured All-Polymeric Lubricant-Infused Films Prevent Thrombosis and Repel Multidrug-Resistant Pathogens. (2022) (0)
- Faculty Opinions recommendation of The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism. (2020) (0)
- Faculty Opinions recommendation of Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. (2020) (0)
- Faculty Opinions recommendation of Hemodynamic regulation of perivalvular endothelial gene expression prevents deep venous thrombosis. (2020) (0)
- Faculty Opinions recommendation of Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. (2020) (0)
- Faculty Opinions recommendation of Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). (2020) (0)
- Heparin and Angiogenesis (2003) (0)
- Faculty Opinions recommendation of PCSK9 induces a pro-inflammatory response in macrophages. (2020) (0)
- Management of Venous Thromboembolism in Routine Clinical Practice - Results from the Global GARFIELD-VTE Registry (2019) (0)
- Abstracts from the CanVECTOR 2021 Annual Conference November 5th, 2021 (2021) (0)
- Faculty Opinions recommendation of American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. (2020) (0)
- Faculty Opinions recommendation of Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. (2020) (0)
- Faculty Opinions recommendation of Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability. (2020) (0)
- Faculty Opinions recommendation of Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. (2020) (0)
- Recent advances in understanding, diagnosing and treating venous thrombosis [version 1; peer review: 2 approved] (2022) (0)
- Faculty Opinions recommendation of Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. (2020) (0)
- 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE. (2022) (0)
- Histidine-rich glycoprotein attenuates catheter thrombosis. (2023) (0)
- Factor V Binding to Multimerin 1: Modulation by Factor V Activation and Binding Sites in the Factor V C1 and C2 Domains. (2006) (0)
- New oral anticoagulants : One Step Closer to Replacing Warfarin (2009) (0)
- Faculty of 1000 evaluation for Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. (2018) (0)
- P4624New onset dementia in incident atrial fibrillation. A large cohort study (2017) (0)
- Anticoagulants Evolving Treatments for Arterial and Venous Thrombosis : Role of the Direct Oral (2016) (0)
- 1190Lifestyle risk factors for non-valvular atrial fibrillation (2017) (0)
- Factor VII genotypes play a role in the protection against myocardial infarction in patients with coronary artery disease (2001) (0)
- Chapter 50 – Coagulation Overview (2006) (0)
- Intrinsic Pathway of Coagulation Offers New Targets to Reduce Thrombosis (2015) (0)
- Faculty Opinions recommendation of Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis. (2020) (0)
- Lysine residues 42, 43, and 44 of thrombin activable fibrinolysis inhibitor contribute to its activation by the thrombin-thrombomodulin complex in a cooperative fashion (2015) (0)
- Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial (2019) (0)
- Faculty Opinions recommendation of Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. (2020) (0)
- Faculty of 1000 evaluation for Coagulation assessment with the new generation of oral anticoagulants. (2017) (0)
- Laboratory assessment of platelet function and coagulation (2008) (0)
- We-W40:1 New anticoagulants for atherothrombosis (2006) (0)
- Strategies: A Scientific Statement From the American Heart Association The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment (2014) (0)
- Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. (2023) (0)
- Corrigendum to “Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE” [Thromb. Res. 2020 Jul; 191:103–112] (2021) (0)
- ISTH Biennial Impact Report: Looking back and looking forward (2022) (0)
- Faculty Opinions recommendation of Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. (2017) (0)
- No Fibrinolytic Benefit of Adjunctive Anticoagulation during Arterial Thrombolysis Induced by tPA Combined with TAFIa Inhibitor in a Rabbit Arterial Thrombosis Model. (2004) (0)
- Role of the tissue factor pathway in the biology of tumor initiating cells11Delphine Garnier and Chloe Milsom equally contributed as first authors (2010) (0)
- Biologie chirurgicale pour le clinicien Thromboprophylaxis in surgical patients (2003) (0)
- Faculty Opinions recommendation of Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. (2020) (0)
- Faculty Opinions recommendation of Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. (2019) (0)
- Reviews, Notes, and Listings: Hematology: Disorders of Thrombosis and Hemostasis: Clinical and Laboratory Practice (1993) (0)
- Role of Plasminogen-Fibrin Interaction in Plasminogen Activation by t-PA. (2004) (0)
- Chapter 52 – Venous Thrombosis (2013) (0)
- Studies into the Mechanism by Which Glycosaminoglycans Potentiate Protein C Activation by Factor Xa. (2004) (0)
- International Society on Thrombosis and Haemostasis: Present and future (2021) (0)
- Faculty Opinions recommendation of Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. (2019) (0)
- Letter to the Editor (2016) (0)
- Erratum: Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores (Journal of Biological Chemistry (2010) 285 (28912-28923) DOI 10.1074/jbc.A110.119107) (2015) (0)
- cells: implications for tumor progression and angiogenesis Oncogenic events regulate tissue factor expression in colorectal cancer (2013) (0)
- Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. (2018) (0)
- Trends in the proportion of women as reviewers, editors, and editorial board members of 15 North American and British medical journals from 2014 to 2019: A retrospective study (2022) (0)
- Antagonists in Patients With Major Bleeding Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K (2013) (0)
- Overview of New Anticoagulant Drugs (2016) (0)
- Identification and characterization of a factor Va-binding site on human prothrombin fragment 2 (2019) (0)
- Role of Thrombin Exosites in Protection from Inhibition by Antithrombin in the Presence of Heparin and Fibrin. (2004) (0)
- Faculty of 1000 evaluation for Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. (2017) (0)
- Faculty Opinions recommendation of Platelets Drive Thrombus Propagation in a Hematocrit and Glycoprotein VI-Dependent Manner in an In Vitro Venous Thrombosis Model. (2020) (0)
- International Society on Thrombosis and Haemostasis, ISTH 2015 Congress: Society Introduction (2015) (0)
- Faculty Opinions recommendation of Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. (2020) (0)
- New approaches to oral anticoagulation: Direct thrombin inhibitors (2009) (0)
- activities of fondaparinux , enoxaparin , and heparin in vitro and in vivo Mechanism of catheter thrombosis : comparison of the antithrombotic (2011) (0)
- Antiplatelet Therapies Targeting Thrombin Signaling Thrombin Signaling in Platelets (2009) (0)
- Case 34-2011: A Man with Memory Loss and Partial Seizures (2012) (0)
- Research April 29 , 2016 Thrombin / Coagulation Models (2016) (0)
- The additive effect of dermatan sulfate and low molecular weight heparins on thrombin inhibition in vitro (1992) (0)
- ANTICOAGULANT PROPERTIES OF HD1, A (PRO)THROMBIN-DIRECTED DNA APTAMER (2007) (0)
- Direct Oral Anticoagulants in the Very Elderly (2023) (0)
- The effect of bivalirudin in combination with ticlopidine on laboratory coagulation parameters and the incidence of clinically significant bleeding in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) and stenting (2000) (0)
- Research and Practice in Thrombosis and Haemostasis – a new ISTH publishing platform for the global thrombosis and hemostasis community (2017) (0)
- Chapter 146 – Acute Coronary Syndromes (2018) (0)
- Faculty Opinions recommendation of American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. (2020) (0)
- THROMBOSIS AND HEMOSTASIS Arterial thrombosis is accelerated in mice de fi cient in histidine-rich glycoprotein (2015) (0)
- RENAL IMPAIRMENT DOES NOT COMPROMISE DABIGATRAN REVERSAL BY IDARUCIZUMAB (2018) (0)
- on a National Heart, Lung and Blood Institute Working Group Guided Antithrombotic Therapy: Current Status and Future Research Direction: Report (2014) (0)
- a monoclonal antibody specific for the free peptide Use of a synthetic homologue of human fibrinopeptide A for production of (2011) (0)
- Faculty Opinions recommendation of Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. (2014) (0)
- Faculty Opinions recommendation of Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. (2014) (0)
- Evaluation of direct oral anticoagulants in superficial-vein thrombosis - Authors' reply. (2017) (0)
- Faculty Opinions recommendation of Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. (2014) (0)
- Extended treatment of venous thromboembolism. (2013) (0)
- Bentracimab for Ticagrelor Reversal in Patients (2021) (0)
- Clinical Science/Translational Research (2019) (0)
- Allosteric modulation of exosite 1 attenuates polyphosphate-catalyzed activation of factor XI by thrombin. (2023) (0)
- Pathogenesis of Atherosclerosis Thrombosis I (2005) (0)
- Deep vein thrombosis (1999) (0)
- Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study (2021) (0)
- Mechanism of batroxobin binding to fibrinogen and fibrin 2 (2013) (0)
- The relationship between antithrombin III levels and the anticoagulant effect of standard heparin (1992) (0)
- New Antithrombotic Drugs: Beyond Aspirin and Heparin (1999) (0)
- Direct Oral Anticoagulation Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves: a Retrospective, Real-World Cohort Study. (2022) (0)
- Response by Weitz and Eikelboom to Letter Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants". (2016) (0)
- Contents, Vol. 57, 1990 (1990) (0)
- Treatments for Acute Ischemic Stroke Gene Therapy for Coagulation Disorders (2016) (0)
- News at XI: Moving Beyond Factor Xa Inhibitors. (2023) (0)
- RECURRENT VENOUS THROMBOEMBOLISM IN PULMONARY EMBOLISM PATIENTS WITH RIGHT VENTRICULAR DYSFUNCTION IN THE HOKUSAI-VTE STUDY (2016) (0)
- The new heparins. (1998) (0)
- Abstract 35: Plasma Fibronectin is a Vital Supportive Factor in Hemostasis and a Unique Self-Limiting Regulator in Thrombosis (2014) (0)
- Faculty Opinions recommendation of Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis. (2017) (0)
- What Is the Future of Factor XI Inhibitors? (2022) (0)
- Faculty Opinions recommendation of Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. (2017) (0)
- In pregnant women with suspected VTE and low/intermediate or unlikely pretest probability, D-dimer rules out VTE at 3 mo (2021) (0)
- OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux? (2006) (0)
- Erratum: Long range communication between exosites 1 and 2 modulates thrombin function (The Journal of Biological Chemistry (2009) 284 (25620-25629)) (2015) (0)
- Low-Molecular-Weight Heparin on Cancellous Bone in Rats A Histomorphometric Comparison of the Effects of Heparin and (2013) (0)
- Apixaban for Extended Treatment of Venous Thromboembolism (2013) (0)
- The A1/A2 polymorphism of glycoprotein IIIa was not a risk factor for adverse events complicating coronary interventionsand the homozygous 807T/873A polymorphisms of the glycoprotein Ia/IIa collagen receptor gene was associated with acute MI (1999) (0)
- Corrigendum to “Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE” [Thromb. Res. 2021 May;201:63–72] (2022) (0)
- Changing paradigms in the management of venous thromboembolism. (2006) (0)
- Bacchus and Schulman New Anticoagulants for Venous Thrombosis 7 of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism (0)
- Zinc2+ Promotes Heparin Binding to Fibrin and Subsequent Formation of Ternary Heparin-Thrombin-Fibrin Complexes. (2005) (0)
- The NOACs: clinical pharmacology (2018) (0)
- Abelacimab for Prevention of Venous Thromboembolism. Reply. (2021) (0)
- Time course of recurrent venous thromboembolic and major bleeding events during anticoagulant therapy with apixaban or enoxaparin/warfarin: analysis of the amplify data using landmark method (2014) (0)
- Faculty of 1000 evaluation for Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. (2017) (0)
- Thrombin Aptamer HD1 Inhibits Prothrombin Activation by Binding Proexosite 1 on Prothrombin. (2005) (0)
- Systemic or Venous Thromboembolism Global Anticoagulant Registry in the Field – Venous Thromboembolism ( GARFIELD-VTE ) Rationale and design (2016) (0)
- Chapter 53 – Pulmonary Embolism (2013) (0)
- Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis (2018) (0)
- Faculty Opinions recommendation of Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2014) (0)
- Abstract 348: Lys 42, 43, 44 and Arg 12 of Thrombin Activable Fibrinolysis Inhibitor Comprise Thrombomodulin Binding Exosite Essential for Exerting Its Antifibrinolytic Activity (2017) (0)
- A Protease TAMER: a nucleic acid‐based anticoagulant (2012) (0)
- Faculty Opinions recommendation of Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. (2016) (0)
- Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications (2019) (0)
- An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces (2017) (0)
- Reversal agents for current and forthcoming direct oral anticoagulants. (2023) (0)
- Recruiting researchers. (2001) (0)
This paper list is powered by the following services:
Other Resources About Jeffrey Weitz
What Schools Are Affiliated With Jeffrey Weitz?
Jeffrey Weitz is affiliated with the following schools:
